Group 1 - Huayi Family plans to invest up to 300 million CNY to acquire 5%-8.09% of Haihe Pharmaceutical's shares, marking a significant move after years of inactivity in external investments [1] - Haihe Pharmaceutical has successfully commercialized three products, including Gumeitini tablets, which received conditional approval in March 2023 and was included in the national medical insurance directory [2] - The company has a strong pipeline with five products in clinical research, including a PI3Kα inhibitor, indicating potential for growth in unmet clinical needs [3] Group 2 - The domestic innovative drug industry is accelerating, with small molecule drugs maintaining an irreplaceable position in clinical treatment due to their convenience and cost-effectiveness [4] - Huayi Family's investment in Haihe Pharmaceutical is a strategic move to optimize its business structure amid challenges in the real estate sector, aiming for predictable returns as Haihe Pharmaceutical is expected to enter a rapid growth phase by 2027 [4] - This investment reflects Huayi Family's recognition of Haihe Pharmaceutical's R&D capabilities and commercial prospects, serving as a crucial step for future business transformation [4]

2025年8月，华丽家族（600503.SH）宣布以不超过3亿元增资海和药物，交易完成后将持有其 5%-8.09% 股权。这一操作并非偶然，而是传统行业上市公司应对转型压力、遵循市场逻辑的具体体 现，其背后有明确的政策依据与现实考量。 一、跨界转型是传统行业的必然选择 一是采用 "战略性财务投资" 的稳健策略，既降低了直接并购的整合风险，也为后续合作预留了空间， 与华丽家族转型初期的审慎需求相适配。 海和药物作为创新药企业，其核心价值体现在技术积累与商业化进展两方面： 其一，研发实力扎实。公司累计承担 8 项国家 "重大新药创制" 科技重大专项课题，构建了十多条研发 管线，3 款产品已实现商业化，5 款产品进入临床阶段。其中，谷美替尼片填补了国内 METex14跳变非 小细胞肺癌一线治疗空白，口服紫杉醇为全球唯一获批的口服剂型，技术壁垒清晰。 其二，商业化步入正轨。2024 年营业收入达3.23亿元，主要来自已上市产品的销售贡献，2025年1-2月 营收0.77亿元，延续增长态势，显示出产品市场认可度逐步提升。 尽管海和药物目前处于亏损状态，但这符合创新药企业前期研发投入大的行业特征，与其拥有的关键技 术价值 ...